CPI-613 (CAS 95809-78-2)
See product citations (4)
QUICK LINKS
CPI-613 is a compound that functions as an inhibitor of enzymes involved in cellular metabolism. It acts by disrupting the tricarboxylic acid (TCA) cycle, also known as the citric acid cycle, which is a key metabolic pathway in cells. By targeting enzymes such as pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, CPI-613 interferes with the production of energy and bio precursors in the cell. This disruption ultimately leads to a decrease in the production of ATP, the main energy currency of the cell, and an increase in reactive oxygen species. The altered metabolic state induced by CPI-613 can have significant effects on the viability and proliferation of cancer cells, making it a promising compound for further investigation in cancer. Its mechanism of action at the molecular level provides insights into the metabolic vulnerabilities of cancer cells and may offer potential avenues for the development of novel strategies.
CPI-613 (CAS 95809-78-2) References
- A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. | Lycan, TW., et al. 2016. PLoS One. 11: e0164244. PMID: 27732654
- Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma. | Egawa, Y., et al. 2018. PLoS One. 13: e0198940. PMID: 29879220
- Pharmacologic treatment with CPI-613 and PS48 decreases mitochondrial membrane potential and increases quantity of autolysosomes in porcine fibroblasts. | Mordhorst, BR., et al. 2019. Sci Rep. 9: 9417. PMID: 31263141
- The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells. | Bellio, C., et al. 2019. Cancers (Basel). 11: PMID: 31671803
- CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling. | Gao, L., et al. 2020. J Exp Clin Cancer Res. 39: 73. PMID: 32345326
- An integrated in vivo and in silico analysis of the metabolism disrupting effects of CPI-613 on embryo-larval zebrafish (Danio rerio). | Hala, D., et al. 2021. Comp Biochem Physiol C Toxicol Pharmacol. 248: 109084. PMID: 34051378
- Targeting mitochondrial metabolism in acute myeloid leukemia. | Rex, MR., et al. 2022. Leuk Lymphoma. 63: 530-537. PMID: 34704521
- The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner. | Arnold, C., et al. 2022. Mol Cancer Ther. 21: 100-112. PMID: 34750196
- Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer. | Lang, L., et al. 2021. J Exp Clin Cancer Res. 40: 393. PMID: 34906193
- In Vitro and In Vivo Metabolism of a Novel Antimitochondrial Cancer Metabolism Agent, CPI-613, in Rat and Human. | Reddy, VB., et al. 2022. Drug Metab Dispos. 50: 361-373. PMID: 35086846
- Development and validation of an LC-MS/MS method for determination of a novel anticancer agent (CPI-613) in human plasma. | Reddy, NR., et al. 2022. Bioanalysis. 14: 253-266. PMID: 35172610
- Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. | Kumstel, S., et al. 2022. PLoS One. 17: e0266601. PMID: 35452495
- Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613. | Guardado Rivas, MO., et al. 2022. PLoS One. 17: e0269620. PMID: 35675354
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CPI-613, 10 mg | sc-482709 | 10 mg | $131.00 |